Difference between revisions of "Section 4: Conclusion (from DOI: 10.1007/s11886-020-01293-2) (Q10992)"
Jump to navigation
Jump to search
(Created claim: named entity (P78): Cardiomyopathies (disease - MeSH descriptor) (Q10853), #quickstatements; #temporary_batch_1592939248955) |
(Created claim: named entity (P78): angiotensin I converting enzyme 2 (gene) (Q10876), #quickstatements; #temporary_batch_1592939248955) |
||
| Property / named entity | |||
| + | |||
| Property / named entity: angiotensin I converting enzyme 2 (gene) / rank | |||
| + | Normal rank | ||
Revision as of 19:07, 23 June 2020
Publication: "Cardiovascular Risks in Patients with COVID-19: Potential Mechanisms and Areas of Uncertainty"published in Curr Cardiol Rep; 2020 04 29 ; 22 (5) 34 DOI: 10.1007/s11886-020-01293-2
| Language | Label | Description | Also known as |
|---|---|---|---|
| English |
Section 4: Conclusion (from DOI: 10.1007/s11886-020-01293-2)
|
Publication: "Cardiovascular Risks in Patients with COVID-19: Potential Mechanisms and Areas of Uncertainty"published in Curr Cardiol Rep; 2020 04 29 ; 22 (5) 34 DOI: 10.1007/s11886-020-01293-2
|
Statements
0 references
0 references
0 references
